StreetAlpha.app
Home › Stocks › GILD

Gilead Sciences, Inc. (GILD)

Healthcare
$170.26
▲ +1.60%
LAST CLOSE · NOV 17

Gilead is a biopharmaceutical company that develops and sells medicines for HIV, hepatitis, cancer and other diseases. It last closed at $170.26 on Nov 17, up 1.60% on the day. GILD reports earnings on Tue, Feb 9, 2027. The average 12-month price target from 13 analysts is $180.23 (+5.9% from the last close), with a high of $200.00 and a low of $131.00. Analyst consensus is Strong Buy, based on the latest ratings from 13 firms (11 buy, 2 hold, 0 sell). Over the past 90 days StreetAlpha recorded 3 whale options trades in GILD, 100% of them bullish and 0% bearish. In the past 30 days there were 28 dark pool prints totaling $47.6M, the largest $10.2M.

AI Auto Pilots
Is GILD in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$31.0B
+6.5% vs a year ago
Net income
−$3.9B
−147.6% vs a year ago
EPS (diluted)
−$3.13
−148.5% vs a year ago
Free cash flow
$13.8B
44.5% margin
Valuation
Market cap
$211B
1.24B shares
P/E
–
No P/E while losing money
Price to sales
6.8
Market cap over revenue
Dividend yield
1.91%
$3.25 a share over 12 months
Balance sheet
Cash & equivalents
$6.4B
At Sep 30
Debt
$26.2B
At Sep 30
Shareholder equity
$13.0B
Buybacks
$1.4B
Last 12 months
CEODaniel O'Day
Employees17,000 (Jul 1, 2026)
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $27.3B$27.3BFY2021FY2022: $27.3B$27.3BFY2022FY2023: $27.1B$27.1BFY2023FY2024: $28.8B$28.8BFY2024FY2025: $29.4B$29.4BFY2025

From GILD's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 30). Last 12 months adds up the four latest quarters.

Next report
Feb 9
2027 · Time not announced
Consensus EPS forecast
$1.24
$8.30B revenue est.
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
Strong Buy
Based on 13 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
13firms
11 Buy2 Hold0 Sell
Each firm's latest rating on GILD in the past 90 days
Average 12-month target
$180.23
▲ 5.9% upside

Based on 13 analysts who set a price target on GILD in the past 90 days. The average target is $180.23, with a high of $200.00 and a low of $131.00, compared with the last close of $170.26.

$115$146$176$206PAST 61 TRADING DAYS12-MONTH TARGETSHIGH $200AVG $180.23LOW $131May 22LAST CLOSE+12 MO$115$146$176$206PAST 61 DAYSTARGETSHIGH $200AVG $180.23LOW $131May 22LAST CLOSE+12 MO
Highest target$200.00
Average target$180.23
Lowest target$131.00
Latest rating changes
BarclaysTarget raised
Nov 16Hold$145 → $160
UBSMaintained
Oct 31Buy$195
JP MorganTarget raised
Oct 30Buy$170 → $190
CitigroupMaintained
Oct 30Buy$188
ScotiabankMaintained
Oct 30Buy$200
DateFirmActionRatingPrice target
Nov 16BarclaysTarget raisedHold$145 → $160
Oct 31UBSMaintainedBuy$195
Oct 30JP MorganTarget raisedBuy$170 → $190
Oct 30CitigroupMaintainedBuy$188
Oct 30ScotiabankMaintainedBuy$200
Loading…

Technical Analysis

GILD · as of the Nov 17 close · updated after every close
Uptrend

The stock is 3% above its 20 day and 8% above its 50 day average. It is 17% above its 200 day average, so the longer trend is still up. Momentum is neutral (RSI 62). The nearest support is the Pivot at $169.11, and the nearest resistance the Pivot R1 at $172.51.

Short trendBullish
Long trendBullish
MomentumNeutral
StretchNormal
VolatilityHigh, 2.7%/day
Key levels
$176.5852 week high+3.7%
$175.65Swing high (Oct 30)+3.2%
$172.51Pivot R1+1.3%
$170.26Last close
$169.11Pivot−0.7%
$166.87Pivot S1−2.0%
$165.5320 day average−2.8%
$164.00Swing low (Nov 6)−3.7%
$155.9050 day average−8.4%
$146.44100 day average−14.0%
$141.99200 day average−16.6%
$116.8852 week low−31.4%
Indicators
RSI (14)61.83Strong, overbought above 70Neutral
MACD4.20Below its signal lineBearish
Stochastic58.4Middle of its rangeNeutral
ADX (14)31.7Trending up
Williams %R-40.2Oversold below −80, overbought above −20Neutral
CCI (20)46.5Oversold below −100, overbought above 100Neutral
Rate of change+1.7%Change over 10 sessionsBullish
ATR (14)$4.66Typical daily range, 2.7% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for GILD

What happened before

See how GILD did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Whale flow leans bullish3 bullish and 0 bearish whale options trades in the last 90 days. See Whale Flow
November seasonalityHow GILD usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How GILD has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
3
Bullish
3
100%
Bearish
0
0%
Date span
Sep 30 – Oct 30
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
28
Notional
$47.6M
Largest print
$10.2M
Loading…

GILD Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲1,143 buying vs 967 selling
  • ▼Held by funds -3.5 pts
  • ▲Funds holding +55
  • ▼Superinvestors: 2 added, 3 cut
  • ▼Put/call 0.30 to 1.00
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding2,3432,288+2.4%
In funds' top 102616+62.5%
Held by funds86.7%90.3%−3.5 pts
New / increased226 / 917125 / 929+8.4%
Reduced / sold out827 / 140850 / 167−4.9%
Put/call ratio1.000.30+233.9%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See GILD institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

GILD Stock Buybacks

See all S&P 500 buybacks →
Spent, 12 months
$1.4B
0.7% yield
Left in program
$5.7B
2.7% of value
Shares outstanding, 12 months
−0.0%
Fewer shares
Last quarter
$504.5M
Sep 2026
Avg price paid, last quarter
$139.28
3.6M shares bought
S&P 500 rank by spending
#144 of 358
 
Spent each quarter, last 3 yearsTop bar $905.7M
Dec 2023: $183.9M, average price $77.51Mar 2024: $516.3M, average price $76.61Jun 2024: $133.2M, average price $66.37Sep 2024: $382.4M, average price $76.32Dec 2024: $397.4M, average price $91.58Mar 2025: $905.7M, average price $104.15Jun 2025: $587.2M, average price $106.10Sep 2025: $572.7M, average price $114.25Dec 2025: $292.6M, average price $119.17Mar 2026: $598.1M, average price $139.49Jun 2026: $416.3M, average price $130.59Sep 2026: $504.5M, average price $139.28
Dec 2023Sep 2026
For membersMonth by month buying, shares and the average price paid each month are shown to AI Starter and AI Pro members.

From the company's 10-Q filed Oct 30, 2026. Quarters are the company's own fiscal quarters. Yield and % of value use the latest close. Buybacks are not a forecast: in our testing, the biggest buyers did about the same as the average S&P 500 stock.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GILD is in one of them and how their past GILD trades turned out.

GILD in the AI portfolios
Loading…

GILD News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered GILD in an article yet. Here's the latest on the wider market.

GILD Congress Trades

All congress trades →
Trades, 12 months
18
Buys
11
61%
Sells
7
39%
People
6
Last filed Nov 11
Who traded GILD · since 2014
Latest 5 filings of 137
$1K – $15KTraded Jun 2, 2026Filed Nov 11, 2026
$1K – $15KTraded Jul 24, 2026Filed Sep 22, 2026
$15K – $50KTraded Jul 23, 2026Filed Sep 22, 2026
$1K – $15KTraded Aug 10, 2026Filed Sep 4, 2026
$1K – $15KTraded Jul 20, 2026Filed Aug 7, 2026
PersonTypeAmountTradedFiledDelay
Arjun ModyExecutive branchSell$1K – $15KJun 2, 2026Nov 11, 2026162 d
Donald J TrumpExecutive branchSell$1K – $15KJul 24, 2026Sep 22, 202660 d
Donald J TrumpExecutive branchBuy$15K – $50KJul 23, 2026Sep 22, 202661 d
Ro KhannaD · CASell$1K – $15KAug 10, 2026Sep 4, 202625 d
Ro KhannaD · CABuy$1K – $15KJul 20, 2026Aug 7, 202618 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Gilead Sciences

Gilead is a biopharmaceutical company based in Foster City, California. It develops and sells medicines for viral diseases, including HIV and hepatitis, along with cancer treatments such as a breast cancer drug and cell therapies for certain blood cancers. Its portfolio also includes an antifungal medicine and a COVID-19 treatment. Gilead sells to hospitals, clinics and other healthcare providers, largely through wholesalers, distributors and partners.

Headquarters
Foster City, CA
Founded
1987